A Phase 3 interventional study of Cyclophosphamide and Doxorubicin in Relapsed or Refractory Follicular Lymphoma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb — 2 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Follicular · Bristol-Myers Squibb.
Among the 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2024, is one of 4 in phase 3, and was the 16th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →2 of the 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Celgene · Sites in United States, Australia, Brazil and 18 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 4 · Phase 3 4
First in 2010; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 61 across the 18 interventional studies, 36 across the 5 observational. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
2 of the studies in Lymphoma, Follicular by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
| NCT07256015Bristol-Myers SquibbDeucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | 2027-07-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Liso-cel compared to standard of care in adults with Relapsed or Refractory Follicular Lymphoma.
The purpose of this phase III study is to evaluate the clinical benefit of liso-cel for the treatment of r/r FL by comparing it to standard of care therapy in patients with r/r FL, with progression-free survival (PFS) as the primary endpoint.
The primary objective is to demonstrate superiority of the Liso-cel treatment strategy over standard of care (SOC) therapy with respect to progression-free survival (PFS) determined by independent review committee (IRC) based on the Lugano response criteria.
Participants randomized to Arm A (Standard of Care) will receive RCHOP, BR, or R2 based on investigator choice and this has to be determined prior to randomization.
Participants randomized to Arm B (Liso-cel treatment) will receive a single infusion CAR-positive viable T-cells.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb.
Compared within Lymphoma, Follicular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Comparators: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) B-R (bendamustine and rituximab) R2 (rituximab and lenalidomide)
Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Rituximab · Drug: Prednisone · Drug: Bendamustine · Drug: Lenalidomide
Lisocabtagene Maraleucel
Drug: Fludarabine · Drug: Liso-cel
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Also known as: Lisocabtagene Maraleucel, BREYANZI
Progression-free survival (PFS)
Defined as the time from randomization to death due to any cause or progressive disease (PD) per independent review committee (IRC) assessment using the Lugano 2014 Criteria, whichever occurs first
Time frame: Up to 5 years from the last participant randomized
Complete response (CR)
Defined as participants achieving a complete response per IRC assessment using the Lugano 2014 Criteria
Time frame: Up to 5 years from the last participant randomized
Overall survival (OS)
Defined as the time from randomization to death due to any cause
Time frame: Up to approximately 7 years
Overall response (OR)
Defined as participants achieving a response (CR or partial response (PR)) per IRC assessment using the Lugano 2014 Criteria
Time frame: Up to 5 years from the last participant randomized
Duration of response (DOR)
Defined as the time from first response (CR or PR) per IRC assessment using the Lugano 2014 Criteria to PD or death due to any cause, whichever occurs first
Time frame: Up to 5 years from the last participant randomized
Event-free survival (EFS)
Defined as the time from randomization to the first documentation of progressive disease (PD) per IRC assessed using the Lugano 2014 Criteria start of new anti-cancer therapy, or death due to any cause, whichever occurs first
Time frame: Up to 5 years from the last participant randomized
Time to next anti-cancer therapy (TTNLT)
Defined as time from randomization to start of new anti-cancer therapy or death due to any cause, whichever occurs first
Time frame: Up to 5 years from the last participant randomized
PFS rate
Time frame: Up to 5 years from the last participant randomized
EFS rate
Time frame: Up to 5 years from the last participant randomized
OS rate
Time frame: Up to approximately 7 years
Progression-free survival on the next line of treatment (PFS-2)
Defined as the time from randomization to death from any cause or tumor progression on next line treatment per Investigator assessment, whichever occurs first
Time frame: Up to 5 years from the last participant randomized
Number of participants with adverse events (AEs)
Time frame: Up to 5 years from the last participant randomized
Number of participants with adverse event of special interest (AESIs)
Time frame: Up to 5 years from the last participant randomized
Number of participants with serious adverse events (SAEs)
Time frame: Up to 5 years from the last participant randomized
Number of participants with laboratory abnormalities
Time frame: Up to 5 years from the last participant randomized
Frequency and length of hospitalizations
Time frame: Up to 5 years from the last participant randomized
Number of participants with intensive care unit (ICU) inpatient days
Time frame: Up to 5 years from the last participant randomized
Number of participants with non-ICU inpatient days
Time frame: Up to 5 years from the last participant randomized
Mean change from baseline in key health-related quality of life (HRQoL) domains.
Key HRQoL Domains: Global health status/quality of life (GHS/QoL), fatigue, pain, physical functioning, role functioning, cognitive functioning from The European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ C30), and Symptom Burden and Physical Condition/Fatigue from the European Quality of Life Module Non-Hodgkin's Lymphoma Low-Grade 20 items (EORTC QLQ-NHL-LG20)
Time frame: Up to 5 years from the last participant randomized
Time to meaningful improvement/deterioration in key HRQoL domains.
Key HRQoL Domains: Global health status/quality of life (GHS/QoL), fatigue, pain, physical functioning, role functioning, cognitive functioning from The European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ C30), and Symptom Burden and Physical Condition/Fatigue from the European Quality of Life Module Non-Hodgkin's Lymphoma Low-Grade 20 items (EORTC QLQ-NHL-LG20)
Time frame: Up to 5 years from the last participant randomized
No study locations are listed for this record.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · www.bms.com
Start is estimated for Mar 2024; primary completion for Oct 2031, 90 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisocabtagene maraleucel
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company →